Everolimus for the treatment of advanced, nonfunctional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

BACKGROUND: Effective systemic therapies for patients with progressive neuroendocrine tumours of lung or gastrointestinal tract are limited. We aimed to assess the efficacy and safety of everolimus in this patient population. METHODS: In RADIANT-4, a randomised, double-blind, placebo-controlled, pha...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Lancet
Egile Nagusiak: Yao, James C, Fazio, Nicola, Singh, Simron, Buzzoni, Roberto, Carnaghi, Carlo, Wolin, Edward, Tomasek, Jiri, Raderer, Markus, Lahner, Harald, Voi, Maurizio, Pacaud, Lida Bubuteishvili, Rouyrre, Nicolas, Sachs, Carolin, Valle, Juan W, Fave, Gianfranco Delle, Van Cutsem, Eric, Tesselaar, Margot, Shimada, Yasuhiro, Oh, Do-Youn, Strosberg, Jonathan, Kulke, Matthew H, Pavel, Marianne E
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6063317/
https://ncbi.nlm.nih.gov/pubmed/26703889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(15)00817-X
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak